Form 4: Director Michael Stansky Increases Stake in TriSalus
Statement of Changes in Beneficial Ownership
Director Michael Stansky acquired 43,590 restricted stock units and 47,003 stock options in TriSalus Life Sciences.
Summary
- Director Michael P. Stansky received 23,501 restricted stock units (RSUs) vesting on May 14, 2027.
- Director received 20,089 RSUs in lieu of 2026 cash board retainer fees, vesting quarterly through 2026.
- Director was granted 47,003 stock options with an exercise price of $2.52, vesting on May 14, 2027.
- Total direct beneficial ownership increased to 830,722 shares of common stock.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral-to-positive event, as it reflects standard director compensation and alignment of interests without signaling major strategic shifts.
Positives
- Director demonstrates alignment with shareholders by electing to receive equity in lieu of cash retainer fees.
- Increased equity stake indicates long-term commitment to the company's growth.
Negatives
- None identified.
Risks
- Vesting of equity awards is contingent upon continued service with the issuer.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation and equity grants.
Management Comments
- The director elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees.
Industry Context
StockSavvy.ai notes that it is common practice for biotech and life sciences companies to utilize equity-based compensation for board members to preserve cash reserves for R&D and clinical trials.
Comparison to Industry Standards
- The use of RSU grants in lieu of cash retainers is a standard corporate governance practice among small-cap life sciences firms to align director interests with long-term shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy | Director elected to receive equity in lieu of cash retainer fees per the Non-Employee Director Compensation Policy. | 05/14/2026 | Positive impact on cash flow preservation. |
Related Party Transactions
- Michael Stansky is the managing member of Skyview Investments LLC, which holds 199,698 shares of the issuer.
Stakeholder Impact
- Shareholders benefit from increased director alignment and cash preservation.
Next Steps
- Vesting of Retainer RSU Award in quarterly installments through 2026.
- Vesting of RSU Award and stock options on May 14, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of grant for RSUs and stock options. |
| 05/13/2036 | Expiration date for the granted stock options. |
Keywords
TriSalus Life Sciences, TLSI, Insider Trading, Form 4, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.